Companies Poseida Therapeutics
Poseida Therapeutics (PSTX): executive pay, fiscal 2023
Free brief. Every figure links to the company’s own filing.
Poseida Therapeutics no longer files a proxy statement; its last pay data is FY2023.
CEO pay, last three years
- $4,369,452FY2022
- $3,818,018FY2023
CEO total pay was $3,818,018 in fiscal 2023, down from $4,369,452 in fiscal 2022.
FY2023: salary $611,667 · bonus $0 · stock awards $1,442,285 · option awards $1,413,936
Executives and directors
Brent Warner · PresidentKristin Yarema · PresidentMark Gergen · CEOCharles M. Baum · Independent DirectorCynthia Collins · Independent DirectorEric Ostertag · Former director (through FY2023)John P. Schmid · Lead Independent DirectorLuke Corning · Independent DirectorMarcea B. Lloyd · Independent DirectorRafael G. Amado · Independent Director
Frequently asked questions
Who was the highest-paid executive at Poseida Therapeutics in fiscal 2023?
As disclosed, Mark Gergen (Chief Executive Officer, President and Chairman) was the highest-paid executive at Poseida Therapeutics in fiscal 2023, with total compensation of $3,818,018.
How much does Poseida Therapeutics spend in total on board compensation for fiscal 2023?
As disclosed, Poseida Therapeutics reported total board compensation of $672,149 for fiscal 2023.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Mark Gergen | $611,667 | $0 | $1,442,285 | $1,413,936 | $336,420 | $0 | $13,710 | $3,818,018 |
| Chief Executive Officer, President and Chairman | ||||||||
| Kristin Yarema | 380,625 | 0 | 934,910 | 934,210 | 171,280 | 0 | 13,540 | 2,434,565 |
| President, Cell Therapy | ||||||||
| Brent Warner | 445,767 | 0 | 496,330 | 486,574 | 200,600 | 0 | 13,181 | 1,642,452 |
| President, Gene Therapy | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Mark Gergen | $3,818,018 | $4,369,452 | — | ↓ −551,434 |
| Kristin Yarema | 2,434,565 | — | — | — |
| Brent Warner | 1,642,452 | 2,879,028 | — | ↓ −1,236,576 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation program is designed to provide appropriate incentives to executives to achieve defined annual performance goals and to reward them for achievement towards these goals. Long-term incentives are provided through equity awards, historically stock options and more recently RSUs, to align executive interests with stockholders.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Consulting, Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Mark Gergen | Option | 10,938 | 16 | — |
| Brent Warner | RSU | 92,772 | — | 496,330 |
| Mark Gergen | Option | 99,750 | 9.15 | — |
| Brent Warner | Option | 101,793 | 5.35 | — |
| Brent Warner | RSU | 230,910 | — | 789,712 |
| Brent Warner | Option | 242,457 | 3.42 | — |
| Mark Gergen | RSU | 267,900 | — | 1,272,525 |
| Mark Gergen | RSU | 269,586 | — | 1,442,285 |
| Mark Gergen | Option | 280,855 | 4.75 | — |
| Mark Gergen | Option | 295,800 | 5.35 | — |
| Kristin Yarema | RSU | 356,836 | — | 934,910 |
| Kristin Yarema | Option | 415,272 | 2.62 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Rafael G. AmadoIndependent · Compensation Committee · Science and Technology Committee (4) (Chair) | $31,667 | $108,468 | $108,037 | — | $0 | $248,172 |
| John P. SchmidIndependent · Audit Committee (Chair) · Nominating and Corporate Governance Committee | 79,000 | 48,536 | 47,573 | — | 0 | 175,109 |
| Cynthia CollinsIndependent · Audit Committee · Compensation Committee (Chair) · Science and Technology Committee (4) | 59,167 | 48,536 | 47,573 | — | 0 | 155,276 |
| Charles M. BaumIndependent · Audit · Compensation · Science and Technology Committee | 54,167 | 48,536 | 47,573 | — | 0 | 150,276 |
| Marcea B. LloydIndependent · Compensation · Nominating and Corporate Governance (Chair) | 53,000 | 48,536 | 47,573 | — | 0 | 149,109 |
| Luke CorningIndependent · Nominating and Corporate Governance Committee | 44,000 | 48,536 | 47,573 | — | 0 | 140,109 |
| Eric OstertagNot independent · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
| Mark J. GergenEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Kristin YaremaEmployee director · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $275,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $321,001 |
| Equity awards (grant-date value) | $351,148 |
| All other compensation | $0 |
| Total cost of the board | $672,149 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Poseida Therapeutics as a peer
Companies that benchmark against PSTX
7 companies name PSTX as a compensation peer
- Adaptimmune Therapeutics PLCADAPFY2024
- C4 Therapeutics, Inc.CCCCFY2025
- Generation Bio Co.GBIOFY2024
- Gossamer Bio, Inc.GOSSFY2025
- Repare Therapeutics Inc.RPTXFY2024
- Stoke Therapeutics, Inc.STOKFY2025
- SUTRO BIOPHARMA, INC.STROFY2025
Each company listed discloses PSTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PSTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Poseida Therapeutics | 2023 | Mark Gergen | $611,667 | $1,442,285 | $1,413,936 | $336,420 | $3,818,018 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-17 | — | — | — | — | — |
| 2023 | 2023-06-15 | — | — | — | — | — |
| 2022 | 2022-06-16 | — | — | — | — | — |
| 2021 | 2021-06-16 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-06-17 | —a |
| 2023 | 2023-06-15 | —b |
| 2022 | 2022-06-16 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Mark J. Gergen | Director | 2025-01-02 | D | 23,313 | $10 | $223,805 | Common | Form 4 ↗ |
| John P. Schmid | Director | 2025-01-08 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John P. Schmid | Director | 2025-01-08 | D | 16,038 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John P. Schmid | Director | 2025-01-08 | D | 32,076 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark J. Gergen | Director | 2025-01-08 | D | 48,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Harry J. Leonhardt | GC & Chief Compliance Officer | 2025-01-08 | D | 137,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kristin Yarema | President and CEO | 2025-01-08 | D | 345,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark J. Gergen | Director | 2025-01-08 | D | 518,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark J. Gergen | Director | 2025-01-08 | D | 636,726 | — | — | Common | Form 4 ↗ |
| Harry J. Leonhardt | GC & Chief Compliance Officer | 2025-01-08 | D | 125,283 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Harry J. Leonhardt | GC & Chief Compliance Officer | 2025-01-08 | D | 72,568 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Harry J. Leonhardt | GC & Chief Compliance Officer | 2025-01-08 | D | 223,640 | — | — | Common | Form 4 ↗ |
| Syed Ali-aamir Rizvi | Chief Medical Officer | 2025-01-08 | D | 250,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johanna Mylet | Chief Financial Officer | 2025-01-08 | D | 111,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johanna Mylet | Chief Financial Officer | 2025-01-08 | D | 125,283 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johanna Mylet | Chief Financial Officer | 2025-01-08 | D | 4,117 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles M. Baum | Director | 2025-01-08 | D | 27,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cynthia Collins | Director | 2025-01-08 | D | 87,440 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marcea B. Lloyd | Director | 2025-01-08 | D | 27,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marcea B. Lloyd | Director | 2025-01-08 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marcea B. Lloyd | Director | 2025-01-08 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marcea B. Lloyd | Director | 2025-01-08 | D | 32,076 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marcea B. Lloyd | Director | 2025-01-08 | D | 68,950 | — | — | Common | Form 4 ↗ |
| John P. Schmid | Director | 2025-01-08 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John P. Schmid | Director | 2025-01-08 | D | 58,950 | — | — | Common | Form 4 ↗ |
| Luke Corning | Director | 2025-01-08 | D | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Luke Corning | Director | 2025-01-08 | D | 45,833 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Luke Corning | Director | 2025-01-08 | D | 58,950 | — | — | Common | Form 4 ↗ |
| Rafael G. Amado | Director | 2025-01-08 | D | 58,950 | — | — | Common | Form 4 ↗ |
| Mark J. Gergen | Director | 2025-01-08 | D | 172,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rafael G. Amado | Director | 2025-01-08 | D | 27,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cynthia Collins | Director | 2025-01-08 | D | 27,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cynthia Collins | Director | 2025-01-08 | D | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark J. Gergen | Director | 2025-01-08 | D | 364,060 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark J. Gergen | Director | 2025-01-08 | D | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark J. Gergen | Director | 2025-01-08 | D | 240,721 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John P. Schmid | Director | 2025-01-08 | D | 25,833 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Luke Corning | Director | 2025-01-08 | D | 27,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kristin Yarema | President and CEO | 2025-01-08 | D | 498,325 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles M. Baum | Director | 2025-01-08 | D | 27,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles M. Baum | Director | 2025-01-08 | D | 78,600 | — | — | Common | Form 4 ↗ |
| Kristin Yarema | President and CEO | 2025-01-08 | D | 615,836 | — | — | Common | Form 4 ↗ |
| Luke Corning | Director | 2025-01-08 | D | 27,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark J. Gergen | Director | 2025-01-08 | D | 342,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Harry J. Leonhardt | GC & Chief Compliance Officer | 2025-01-08 | D | 111,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Harry J. Leonhardt | GC & Chief Compliance Officer | 2025-01-08 | D | 160,385 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Syed Ali-aamir Rizvi | Chief Medical Officer | 2025-01-08 | D | 185,000 | — | — | Common | Form 4 ↗ |
| Johanna Mylet | Chief Financial Officer | 2025-01-08 | D | 72,568 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johanna Mylet | Chief Financial Officer | 2025-01-08 | D | 65,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johanna Mylet | Chief Financial Officer | 2025-01-08 | D | 82,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johanna Mylet | Chief Financial Officer | 2025-01-08 | D | 35,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johanna Mylet | Chief Financial Officer | 2025-01-08 | D | 254,852 | — | — | Common | Form 4 ↗ |
| Charles M. Baum | Director | 2025-01-08 | D | 57,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cynthia Collins | Director | 2025-01-08 | D | 27,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cynthia Collins | Director | 2025-01-08 | D | 58,950 | — | — | Common | Form 4 ↗ |
| Marcea B. Lloyd | Director | 2025-01-08 | D | 27,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marcea B. Lloyd | Director | 2025-01-08 | D | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marcea B. Lloyd | Director | 2025-01-08 | D | 25,833 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marcea B. Lloyd | Director | 2025-01-08 | D | 16,038 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John P. Schmid | Director | 2025-01-08 | D | 27,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John P. Schmid | Director | 2025-01-08 | D | 27,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John P. Schmid | Director | 2025-01-08 | D | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rafael G. Amado | Director | 2025-01-08 | D | 55,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Malin Life Sciences Holdings Ltd | Greater-than-10% holder | 2025-01-08 | D | 11,835,673 | — | — | Common | Form 4 ↗ |
| Johanna Mylet | Chief Financial Officer | 2025-01-08 | D | 80,192 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (83 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Mark Gergen. DEF 14A, filed 2024-04-25. Section “Executive Compensation”. As printed: 3,818,018. View filing ↗
- Section 01, Kristin Yarema. DEF 14A, filed 2024-04-25. Section “Executive Compensation”. As printed: 2,434,565. View filing ↗
- Section 01, Brent Warner. DEF 14A, filed 2024-04-25. Section “Executive Compensation”. As printed: 1,642,452. View filing ↗
- Section 08, Rafael G. Amado. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 248,172. View filing ↗
- Section 08, John P. Schmid. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 175,109. View filing ↗
- Section 08, Cynthia Collins. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 155,276. View filing ↗
- Section 08, Charles M. Baum. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 150,276. View filing ↗
- Section 08, Marcea B. Lloyd. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 149,109. View filing ↗
- Section 08, Luke Corning. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 140,109. View filing ↗
- Section 08, Eric Ostertag. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Mark J. Gergen. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Kristin Yarema. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Mark J. Gergen 2025-01-02. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John P. Schmid 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John P. Schmid 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John P. Schmid 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark J. Gergen 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Harry J. Leonhardt 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristin Yarema 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark J. Gergen 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark J. Gergen 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Harry J. Leonhardt 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Harry J. Leonhardt 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Harry J. Leonhardt 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Syed Ali-aamir Rizvi 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johanna Mylet 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johanna Mylet 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johanna Mylet 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles M. Baum 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia Collins 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcea B. Lloyd 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcea B. Lloyd 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcea B. Lloyd 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcea B. Lloyd 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcea B. Lloyd 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John P. Schmid 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John P. Schmid 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Luke Corning 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Luke Corning 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Luke Corning 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rafael G. Amado 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark J. Gergen 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rafael G. Amado 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia Collins 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia Collins 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark J. Gergen 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark J. Gergen 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark J. Gergen 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John P. Schmid 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Luke Corning 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristin Yarema 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles M. Baum 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles M. Baum 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristin Yarema 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Luke Corning 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark J. Gergen 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Harry J. Leonhardt 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Harry J. Leonhardt 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Syed Ali-aamir Rizvi 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johanna Mylet 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johanna Mylet 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johanna Mylet 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johanna Mylet 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johanna Mylet 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles M. Baum 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia Collins 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia Collins 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcea B. Lloyd 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcea B. Lloyd 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcea B. Lloyd 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcea B. Lloyd 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John P. Schmid 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John P. Schmid 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John P. Schmid 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rafael G. Amado 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Malin Life Sciences Holdings Ltd 2025-01-08. Form 4, filed 2025-01-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johanna Mylet 2025-01-08. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-18. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-16. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-06-16. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 321,001 + equity 351,148 + all other 0 = 672,149, summed across the director compensation table rows.
- Poseida Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Poseida Therapeutics's own proxy. As printed: 3,818,018. View filing ↗